Fly News Breaks for January 14, 2020
Jan 14, 2020 | 06:33 EDT
JMP Securities analyst Reni Benjamin raised his price target on Incyte (INCY) to $121 and kept his Outperform rating after the company announced a global collaboration and license agreement for tafasitamab with MorphoSys (MOR) yesterday. Despite the $900M cash payment upon closing by Incyte, the analyst believes that the deal is net-positive for both companies as Incyte gains a "significant" mid-to-long term revenue driver while MorphoSys gets access to its established "hematology/oncology network and expertise."
News For INCY;MOR From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.